Researchers investigated the protein expression of interleukin (IL)-41 in the synovial tissue of patients with psoriatic arthritis, rheumatoid arthritis, and osteoarthritis and evaluated the production of IL-41 from the enthesis.
Researchers conducted a comparison study of outcomes in patients with psoriatic arthritis treated with secukinumab, apremilast, and other biologic medications.
This study was conducted to describe patterns of first and subsequent TNFi use and response to long-term TNFi therapy in patients with PsA.
Guselkumab (Tremfya) is already approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
The study compared the benefits and drug survival of patients with psoriatic arthritis who did not fulfill vs those who did fulfill the inclusion criteria for randomized controlled trials for the TNF inhibitor chosen for their treatment.
The study assessed the comparative effectiveness of secukinumab and etanercept in patients with psoriatic arthritis who were biologic-naive.
Researchers reviewed the biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis.
The prevalence of neuropathic-like pain was found to be high in patients with psoriatic arthritis, a condition that may be associated with higher disease activity and fibromyalgia.
In a post hoc analysis of the ASTRAEA study, researchers evaluated the effect of BMI on subsequent response to abatacept in psoriatic arthritis.
Inflammation, disease duration, and chronic pain were identified as the main factors underlying fatigue experienced by patients with psoriatic arthritis.